Circulating fibrocytes and Crohn's disease

British Journal of Surgery

Volumn 100, Issue 12, 2013, Pages 1549-1556

  Sahebally, S M ^a,b   Burke, J P ^a   Chang, K H ^a   Kiernan, M G ^b   O'Connell, P R ^c,d   Coffey, J C ^a,b  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

CELL DIFFERENTIATION; CROHN DISEASE; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; HUMAN; INTESTINE; PATHOLOGY; PHYSIOLOGY; REVIEW;

CELL DIFFERENTIATION; CROHN DISEASE; CYTOKINES; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; INTESTINES;

EID: 84885405443     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9302     Document Type: Review

References (85)

1. Baumgart DC, Sandborn WJ,. Crohn's disease. Lancet 2012; 380: 1590-1605.
2. Jussila A, Virta LJ, Kautiainen H, Rekiaro M, Nieminen U, Färkkilä MA,. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis 2012; 18: 555-561.
3. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR,. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007; 102: 439-448.
4. Van Assche G, Geboes K, Rutgeerts P,. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 2004; 10: 55-60.
5. Bernell O, Lapidus A, Hellers G,. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38-45.
6. Aarnio MT, Mecklin JP, Voutilainen M,. The role of surgery in Crohn's disease: a retrospective analysis from a single hospital. Scand J Surg 2010; 99: 208-212.
7. Dietz DW, Laureti S, Strong SA, Hull TL, Church J, Remzi FH, et al,. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. J Am Coll Surg 2001; 192: 330-337.
8. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M,. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963.
9. Jones DW, Finlayson SR,. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg 2010; 252: 307-312.
10. Burke JP, Velupillai Y, O'Connell PR, Coffey JC,. National trends in intestinal resection for Crohn's disease in the post-biologic era. Int J Colorectal Dis 2013; [Epub ahead of print].
11. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al,. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 1907-1913.
12. Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S, et al,. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988; 94: 257-265.
13. Beddy D, Watson RW, Fitzpatrick JM, O'Connell PR,. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg 2004; 91: 72-77.
14. Graham MF,. Pathogenesis of intestinal strictures in Crohn's diseaseâan update. Inflamm Bowel Dis 1995; 1: 220-227.
15. Pucilowska JB, Williams KL, Lund PK,. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000; 279: G653-G659.
16. Regan MC, Flavin BM, Fitzpatrick JM, O'Connell PR,. Stricture formation in Crohn's disease: the role of intestinal fibroblasts. Ann Surg 2000; 231: 46-50.
17. Finesmith TH, Broadley KN, Davidson JM,. Fibroblasts from wounds of different stages of repair vary in their ability to contract a collagen gel in response to growth factors. J Cell Physiol 1990; 144: 99-107.
18. Dennler S, Laboureau J, Farge D, Mauviel A, Verrecchia F,. [ Involvement of TGFbeta1 in fibrotic diseases: role of its effectors, the Smad proteins.] Rev Med Interne 2006; 27: 46-49.
19. McKaig BC, Hughes K, Tighe PJ, Mahida YR,. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002; 282: C172-C182.
20. Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G, et al,. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm Bowel Dis 2008; 14: 1197-1204.
21. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, et al,. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009; 58: 777-789.
22. Fiocchi C., TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 2001; 108: 523-526.
23. Rosin NL, Falkenham A, Sopel MJ, Lee TD, Légaré JF,. Regulation and role of connective tissue growth gactor in AngII-induced myocardial fibrosis. Am J Pathol 2013; 182: 714-726.
24. Mulsow JJ, Watson RW, Fitzpatrick JM, O'Connell PR,. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg 2005; 242: 880-887.
25. Beddy D, Mulsow J, Watson RW, Fitzpatrick JM, O'Connell PR,. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg 2006; 93: 1290-1296.
26. Burke JP, Watson RW, Murphy M, Docherty NG, Coffey JC, O'Connell PR,. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor β1-mediated activation of intestinal fibroblasts. Br J Surg 2009; 96: 541-551.
27. Kapur NK, Wilson S, Yunis AA, Qiao X, Mackey E, Paruchuri V, et al,. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation 2012; 125: 2728-2738.
28. Finnson KW, Philip A,. Endoglin in liver fibrosis. J Cell Commun Signal 2012; 6: 1-4.
29. Docherty NG, Lõpez-Novoa JM, Arevalo M, Düwel A, Rodriguez-Peña A, Pérez-Barriocanal F, et al,. Endoglin regulates renal ischaemia-reperfusion injury. Nephrol Dial Transplant 2006; 21: 2106-2119.
30. Burke JP, Watson RW, Mulsow JJ, Docherty NG, Coffey JC, O'Connell PR,. Endoglin negatively regulates transforming growth factor β1-induced profibrotic responses in intestinal fibroblasts. Br J Surg 2010; 97: 892-901.
31. Leask A, Abraham DJ,. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-827.
32. Lutz M, Knaus P,. Integration of the TGF-beta pathway into the cellular signalling network. Cell Signal 2002; 14: 977-988.
33. Sorrentino D., Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion 2008; 77: 38-47.
34. Sorrentino D, Avellini C, Beltrami CA, Pasqual E, Zearo E,. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006; 21: 276-281.
35. Pallotta N, Barberani F, Hassan NA, Guagnozzi D, Vincoli G, Corazziari E,. Effect of infliximab on small bowel stenoses in patients with Crohn's disease. World J Gastroenterol 2008; 14: 1885-1890.
36. Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC,. Infliximab treatment for symptomatic Crohn's disease strictures. Aliment Pharmacol Ther 2009; 29: 279-285.
37. Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S,. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol 1998; 30: 909-922.
38. Pucilowska JB, McNaughton KK, Mohapatra NK, Hoyt EC, Zimmermann EM, Sartor RB, et al,. IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1307-G1322.
39. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al,. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 438-446.
40. Sakai N, Wada T, Yokoyama H, Lipp M, Ueha S, Matsushima K, et al,. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci U S A 2006; 103: 14 098-14 103.
41. Keeley EC, Mehrad B, Strieter RM,. The role of fibrocytes in fibrotic diseases of the lungs and heart. Fibrogenesis Tissue Repair 2011; 4: 2.
42. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, et al,. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006; 45: 429-438.
43. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM,. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007; 353: 104-108.
44. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al,. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588-594.
45. Wang CH, Huang CD, Lin HC, Lee KY, Lin SM, Liu CY, et al,. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit Care Med 2008; 178: 583-591.
46. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S,. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003; 171: 380-389.
47. Zulli A, Buxton BF, Black MJ, Hare DL,. CD34 class III positive cells are present in atherosclerotic plaques of the rabbit model of atherosclerosis. Histochem Cell Biol 2005; 124: 517-522.
48. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, et al,. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006; 103: 18 284-18 289.
49. Varcoe RL, Mikhail M, Guiffre AK, Pennings G, Vicaretti M, Hawthorne WJ, et al,. The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost 2006; 4: 1125-1133.
50. Yang L, Scott PG, Dodd C, Medina A, Jiao H, Shankowsky HA, et al,. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 2005; 13: 398-404.
51. Wang J, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE,. Improvement in postburn hypertrophic scar after treatment with IFN-alpha2b is associated with decreased fibrocytes. J Interferon Cytokine Res 2007; 27: 921-930.
52. Barth PJ, Ebrahimsade S, Ramaswamy A, Moll R,. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions. Virchows Arch 2002; 440: 298-303.
53. LaPar DJ, Burdick MD, Emaminia A, Harris DA, Strieter BA, Liu L, et al,. Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann Thorac Surg 2011; 92: 470-477.
54. Saunders R, Siddiqui S, Kaur D, Doe C, Sutcliffe A, Hollins F, et al,. Fibrocyte localization to the airway smooth muscle is a feature of asthma. J Allergy Clin Immunol 2009; 123: 376-384.
55. Kimura S, Asaka M, Atsumi H, Imura J, Fujimoto K, Chikazawa Y, et al,. Circulating fibrocytes in ischemia-reperfusion injury and chronic renal allograft fibrosis. Nephron Clin Pract 2012; 121: c16-c24.
56. Sakai N, Wada T, Matsushima K, Bucala R, Iwai M, Horiuchi M, et al,. The renin-angiotensin system contributes to renal fibrosis through regulation of fibrocytes. J Hypertens 2008; 26: 780-790.
57. Hong KM, Burdick MD, Phillips RJ, Heber D, Strieter RM,. Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. FASEB J 2005; 19: 2029-2031.
58. Uehara H, Nakagawa T, Katsuno T, Sato T, Isono A, Noguchi Y, et al,. Emergence of fibrocytes showing morphological changes in the inflamed colonic mucosa. Dig Dis Sci 2010; 55: 253-260.
59. Wang JF, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE,. Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen 2007; 15: 113-121.
60. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D,. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008; 83: 1323-1333.
61. Ebihara Y, Masuya M, Larue AC, Fleming PA, Visconti RP, Minamiguchi H, et al,. Hematopoietic origins of fibroblasts: II. In vitro studies of fibroblasts, CFU-F, and fibrocytes. Exp Hematol 2006; 34: 219-229.
62. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R,. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36: 598-606.
63. Hong KM, Belperio JA, Keane MP, Burdick MD, Strieter RM,., Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma,. J Biol Chem 2007; 282: 22 910-22 920.
64. Bucala R, Spiegel LA, Chesney J,. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81.
65. Mori L, Bellini A, Stacey MA, Schmidt M, Mattoli S,. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 2005; 304: 81-90.
66. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB,. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006; 35: 175-181.
67. Cowper SE, Bucala R,. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003; 25: 358.
68. Pilling D, Tucker NM, Gomer RH,. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 2006; 79: 1242-1251.
69. Gordon S, Taylor PR,. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
70. Tacke F, Randolph GJ,. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211: 609-618.
71. Bellini A, Mattoli S,. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007; 87: 858-870.
72. Shelley-Fraser G, Borley NR, Warren BF, Shepherd NA,. The connective tissue changes of Crohn's disease. Histopathology 2012; 60: 1034-1044.
73. Abe R, Donnelly SC, Peng T,. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166: 7556-7562.
74. Niedermeier M, Reich B, Rodriguez Gomez M, Denzel A, Schmidbauer K, Göbel N, et al,. CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci U S A 2009; 106: 17 892-17 897.
75. Loeschke K, Kaltenthaler P,. [ Procollagen-III-peptide in the serum of patients with Crohn disease.] Z Gastroenterol 1989; 27: 137-139.
76. De Simone M, Cioffi U, Contessini-Avesani E, Oreggia B, Paliotti R, Pierini A, et al,. Elevated serum procollagen type III peptide in splanchnic and peripheral circulation of patients with inflammatory bowel disease submitted to surgery. BMC Gastroenterol 2004; 4: 29.
77. Kjeldsen J, Schaffalitzky de Muckadell OB, Junker P,. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy. Gut 1995; 37: 805-810.
78. Koutroubakis IE, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M, Maniatis AN, et al,. Serum laminin and collagen IV in inflammatory bowel disease. J Clin Pathol 2003; 56: 817-820.
79. Rieder F, Fiocchi C,. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol 2008; 24: 462-468.
80. Metz CN,. Fibrocytes: a unique cell population implicated in wound healing. Cell Mol Life Sci 2003; 60: 1342-1350.
81. Dotan I, Werner L, Vigodman S, Weiss S, Brazowski E, Maharshak N, et al,. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010; 16: 583-592.
82. Bailey JR, Bland PW, Tarlton JF, Peters I, Moorghen M, Sylvester PA, et al,. IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells? PloS One 2012; 7: e52332.
83. Maharjan AS, Pilling D, Gomer RH,. Toll-like receptor 2 agonists inhibit human fibrocyte differentiation. Fibrogenesis Tissue Repair 2010; 3: 23.
84. Cario E, Gerken G, Podolsky DK,. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007; 132: 1359-1374.
85. Mehrad B, Burdick MD, Strieter RM,. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009; 41: 1708-1718.